Published in Drug Saf on January 01, 2001
Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. Schizophr Res (2008) 1.03
Impact on cardiovascular events of increasing high density lipoprotein cholesterol with and without lipid lowering drugs. Heart (2005) 0.93
Psoriasis and comorbidities: links and risks. Clin Cosmet Investig Dermatol (2014) 0.88
Genome-wide association analyses suggest NELL1 influences adverse metabolic response to HCTZ in African Americans. Pharmacogenomics J (2013) 0.87
Differential postprandial lipoprotein responses in type 2 diabetic men with and without clinical evidence of a former myocardial infarction. Rev Diabet Stud (2005) 0.85
Does the Prevalence of Dyslipidemias Differ between Newfoundland and the Rest of Canada? Findings from the Electronic Medical Records of the Canadian Primary Care Sentinel Surveillance Network. Front Cardiovasc Med (2015) 0.84
Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile? Cardiovasc Diabetol (2016) 0.81
Effect of experimental hyperlipidaemia on the electrocardiographic effects of repeated doses of halofantrine in rats. Br J Pharmacol (2010) 0.77
Single and mixed dyslipidaemia in Canadian primary care settings: findings from the Canadian primary care sentinel surveillance network database. BMJ Open (2015) 0.77
Lipid abnormalities induced by novel antipsychotic drugs. Drug Saf (2001) 0.75
Apolipoprotein C-II: New findings related to genetics, biochemistry, and role in triglyceride metabolism. Atherosclerosis (2017) 0.75
The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med (1995) 6.73
Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme. Lancet (1995) 5.02
The completeness of medication histories in hospital medical records of patients admitted to general internal medicine wards. Br J Clin Pharmacol (2000) 3.43
Pharmacogenetics: from bench to byte--an update of guidelines. Clin Pharmacol Ther (2011) 3.36
Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol (1997) 3.02
Antihypertensive drug therapies and the risk of ischemic stroke. Arch Intern Med (2001) 2.24
Risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine. Ann Pharmacother (2001) 2.14
Benzodiazepines and the risk of falling leading to femur fractures. Dosage more important than elimination half-life. Arch Intern Med (1995) 2.13
Highly variable anticoagulant response after subcutaneous administration of high-dose (12,500 IU) heparin in patients with myocardial infarction and healthy volunteers. Circulation (1992) 2.10
Methods to assess intended effects of drug treatment in observational studies are reviewed. J Clin Epidemiol (2004) 2.03
Evaluation of the effects of single-nucleotide polymorphisms in CYP3A4 and CYP4F2 on stable phenprocoumon and acenocoumarol maintenance doses. J Thromb Haemost (2013) 1.98
Sex differences in the pharmacological treatment of hypertension: a review of population-based studies. J Hypertens (1997) 1.62
Population pharmacokinetics and relationship between demographic and clinical variables and pharmacokinetics of gentamicin in neonates. Ther Drug Monit (2002) 1.60
A cytochrome b5 is required for full activity of flavonoid 3', 5'-hydroxylase, a cytochrome P450 involved in the formation of blue flower colors. Proc Natl Acad Sci U S A (1999) 1.54
Simpson's paradox: an example from hospital epidemiology. Epidemiology (2000) 1.51
Women with angina pectoris receive less antiplatelet treatment than men. Br J Gen Pract (1999) 1.51
Reproducibility of childhood respiratory symptom questions. Eur Respir J (1992) 1.49
Pharmacogenetics: from bench to byte. Clin Pharmacol Ther (2008) 1.40
A nested case-control study on mortality in users of ibopamine. Neth J Med (1997) 1.39
Ruptured abdominal aortic aneurysms: factors influencing postoperative mortality and long-term survival. Eur J Vasc Endovasc Surg (1998) 1.39
Cardiovascular diseases and risk factors in a population-based study in The Netherlands: agreement between questionnaire information and medical records. Neth J Med (1999) 1.22
Global trends in the incidence and prevalence of type 2 diabetes in children and adolescents: a systematic review and evaluation of methodological approaches. Diabetologia (2013) 1.18
Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res (1994) 1.18
Comparison of various measures for assessing medication refill adherence using prescription data. Pharmacoepidemiol Drug Saf (2009) 1.18
Comparison of different methods to estimate prevalence of drug use by using pharmacy records. J Clin Epidemiol (2001) 1.17
Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study. Osteoporos Int (2010) 1.17
The onset of rheumatoid arthritis in relation to pregnancy and childbirth. Clin Exp Rheumatol (1993) 1.13
Long term persistence with statin treatment in daily medical practice. Heart (2004) 1.13
Extrapyramidal syndromes associated with selective serotonin reuptake inhibitors: a case-control study using spontaneous reports. Int Clin Psychopharmacol (2002) 1.12
Hapten-induced colitis associated with maintained Th1 and inflammatory responses in IFN-gamma receptor-deficient mice. Eur J Immunol (2000) 1.12
Use of statins is associated with an increased risk of rheumatoid arthritis. Ann Rheum Dis (2011) 1.10
Control of blood pressure and risk of stroke among pharmacologically treated hypertensive patients. Stroke (2000) 1.10
Influence of question structure on the recall of self-reported drug use. J Clin Epidemiol (2000) 1.10
Current use of thiazide diuretics and prevention of femur fractures. J Clin Epidemiol (1996) 1.09
VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement. Clin Pharmacol Ther (2006) 1.08
A drug use review study in patients with obstructive lung disease. Assessment of the quality of drug therapy. Pharm Weekbl Sci (1992) 1.07
Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIV-care. J Clin Pharm Ther (2004) 1.07
Postpneumonectomy pulmonary edema. A retrospective analysis of incidence and possible risk factors. Chest (1997) 1.06
Outcome of rheumatoid arthritis in relation to age and rheumatoid factor at diagnosis. J Rheumatol (1993) 1.05
Agreement between self-reported antihypertensive drug use and pharmacy records in a population-based study in The Netherlands. Pharm World Sci (1999) 1.05
Interpretation and inference in noninferiority randomized controlled trials in drug research. Clin Pharmacol Ther (2010) 1.02
Potential impact of benzodiazepine use on the rate of hip fractures in five large European countries and the United States. Calcif Tissue Int (2012) 1.00
An enzyme-linked immunosorbent assay (ELISA) for the measurement of plasmin-alpha 2-antiplasmin complex in human plasma--application to the detection of in vivo activation of the fibrinolytic system. Thromb Haemost (1986) 1.00
Undertreatment of hypercholesterolaemia: a population-based study. Br J Clin Pharmacol (2003) 0.98
Incidence rates and trends of hip/femur fractures in five European countries: comparison using e-healthcare records databases. Calcif Tissue Int (2014) 0.96
A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients. Br J Cancer (2010) 0.96
Is placebo analgesia mediated by endogenous opioids? A systematic review. Pain (1998) 0.93
Selection of oncology medicines in low- and middle-income countries. Ann Oncol (2014) 0.93
Initiation of glucose-lowering therapy in Type 2 diabetes mellitus patients in general practice. Diabet Med (2004) 0.91
Prevalence and determinants of undertreatment of hypertension in the Netherlands. J Hum Hypertens (2004) 0.89
Within-patient variability of myogenic motor-evoked potentials to multipulse transcranial electrical stimulation during two levels of partial neuromuscular blockade in aortic surgery. Anesth Analg (1999) 0.89
Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implications. Eur J Clin Pharmacol (2014) 0.89
Undertreatment of hypertension in a population-based study in The Netherlands. J Hypertens (1998) 0.89
Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa. Br J Clin Pharmacol (2002) 0.88
Reduced in-hospital survival rates of out-of-hospital cardiac arrest victims with obstructive pulmonary disease. Resuscitation (2012) 0.88
Sex differences in antihypertensive drug use: determinants of the choice of medication for hypertension. J Hypertens (1998) 0.87
Risk of fracture in patients with Parkinson's disease. Osteoporos Int (2013) 0.87
Evaluation of antiparkinsonian drugs in pharmacy records as a marker for Parkinson's disease. Pharm World Sci (2001) 0.87
The risk for breast cancer is not evidently increased in women with hyperprolactinemia. Pituitary (2010) 0.86
Genetic variation in the renin-angiotensin system modifies the beneficial effects of ACE inhibitors on the risk of diabetes mellitus among hypertensives. J Hum Hypertens (2008) 0.86
Determinants of DNA yield and purity collected with buccal cell samples. Eur J Epidemiol (2009) 0.86
Polymorphisms of the renin-angiotensin system are associated with blood pressure, atherosclerosis and cerebral white matter pathology. J Neurol Neurosurg Psychiatry (2007) 0.86
Pathogenic potential and horizontal gene transfer in ovine gastrointestinal Escherichia coli. J Appl Microbiol (2009) 0.86
Combined influence of proton-pump inhibitors, calcium-channel blockers and CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention. J Thromb Haemost (2011) 0.85
Are atypical nevi a risk factor for uveal melanoma? A case-control study. J Invest Dermatol (1994) 0.85
Application of routine electronic health record databases for pharmacogenetic research. J Intern Med (2014) 0.85
Use of prevalence and incidence measures to describe age-related prescribing of antidepressants with and without anticholinergic effects. J Clin Epidemiol (2000) 0.84
Non-compliance in elderly people: evaluation of risk factors by longitudinal data analysis. Pharm World Sci (1996) 0.84
Carbon nanoparticles in lateral flow methods to detect genes encoding virulence factors of Shiga toxin-producing Escherichia coli. Anal Bioanal Chem (2010) 0.83
Influence of skinfold thickness on heparin absorption. Lancet (1991) 0.83
A rapid method to estimate the incidence rate and prevalence of insulin-dependent diabetes mellitus in children 0-19 years of age. Pharm World Sci (1995) 0.83
Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. J Clin Endocrinol Metab (2009) 0.82
Estimating the prevalence of hypertension corrected for the effect of within-person variability in blood pressure. J Clin Epidemiol (2000) 0.82
The contribution of six polymorphisms to cardiovascular risk in a Dutch high-risk primary care population: the HIPPOCRATES project. J Hum Hypertens (2009) 0.82
Prognostic factors of early metastasis and mortality in dogs with appendicular osteosarcoma after receiving surgery: an individual patient data meta-analysis. Prev Vet Med (2013) 0.82
The association between antihypertensive drug therapies and plasma lipid levels in the general population. J Hum Hypertens (2001) 0.82
In vitro method for measurement of cardiac performance and responses to inotropic drugs after experimentally induced myocardial infarction in the rat. J Pharmacol Methods (1989) 0.82
Identification of responders and reactive domains to rivastigmine in Alzheimer's disease. Pharmacoepidemiol Drug Saf (2007) 0.82
Fracture rate in patients with myasthenia gravis: the general practice research database. Osteoporos Int (2012) 0.82